China
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 1 386 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 41 (40–43) 3 (2.9–3.1)
Mortality (HIV+TB only) 0.67 (0.23–1.3) 0.05 (0.02–0.1)
Prevalence  (includes HIV+TB) 1 300 (1 100–1 500) 94 (82–107)
Incidence  (includes HIV+TB) 980 (910–1 100) 70 (66–77)
Incidence (HIV+TB only) 4.5 (4.3–9.9) 0.33 (0.31–0.72)
Case detection, all forms (%) 87 (79–93)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 5.7 (4.5–7) 26 (22–30)
MDR-TB cases among notified pulmonary
TB cases
45 000 (35 000–55 000) 9 200 (7 800–11 000)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 275 915   28 025
Pulmonary, clinically diagnosed 512 469    
Extrapulmonary 30 767    
       
Total new and relapse 847 176    
Previously treated, excluding relapses 8 065    
Total cases notified 855 241    
Among 847 176 new and relapse cases:
4 830 (<1%) cases aged under 15 years; male:female ratio: 2.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 30 156 (11%) 11 656 (32%) 41 812
Laboratory-confirmed RR-/MDR-TB cases     4 183
Patients started on MDR-TB treatment     2 184
TB/HIV 2013 Number (%)
TB patients with known HIV status 329 415 (39)
HIV-positive TB patients 4 649 (1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 3 127 (67)
HIV-positive people screened for TB 358 345  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 95
Previously treated cases, excluding relapse, registered in 2012 90
HIV-positive TB cases, all types, registered in 2012 47
RR-/MDR-TB cases started on second-line treatment in 2011 50
XDR-TB cases started on second-line treatment in 2011 25
Laboratories 2013  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 4.6
Drug susceptibility testing (per 5 million population) 0.9
Sites performing Xpert MTB/RIF 160
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 347
% Funded domestically 78%
% Funded internationally 3%
% Unfunded 19%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-01 Data: www.who.int/tb/data